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Purpose of the study
To compare ART initiation with 2NRTI+NNRTI versus
2NRTI+PI through a retrospective analysis and incorpo-
rate these results in a cost-effectiveness analysis.
Methods
Time to regimen switch (discontinuing at least one
ARV) due to VF (two consecutive viral loads >50 cps/ml
after viral suppression or 6-months unreached viral sup-
pression), time to regimen switch due to any other rea-
son and time to resistance development were calculated
using survival analysis. Log-rank test for equality of sur-
vivor functions was used for comparison. Average
4-months absolute increase in CD4 cell count was com-
pared using weighted linear least squares. Cost-effective-
ness analysis was performed using a microsimulation
discrete events model with a lifetime time horizon and
5% discount rate. All resources valued at 2009 prices.
The hospital’s perspective was assumed.
Summary of results
The retrospective analysis was performed on a cohort of
317 HIV-1 infected naïve to ART individuals followed at
an HIV Unit in Portugal (Centro Hospitalar de Cascais).
All (unrandomized) patients in the analysis initiated
ART between 2000 and 2008 with either 2NRTI
+NNRTI (158) or 2NRTI+PI (159). Median age was 39
years-old, 33% were women, and 29.7% were HCV co-
infected. Median (IQR) CD4 count and log10 viral load
were 229 (121—350) cells/mm
3 and 5.0 (4.3—5.5) log
cp/ml. Groups were identical with respect to these char-
acteristics. Equally of Kaplan-Meier survival curves
could not be rejected with respect to: time to switch
due to VF, time to viral suppression and time to resis-
tance development. In the first 3 years, no statistically
significant difference between groups was found in CD4
cell count change. Median (95% CI) time to any ARV
switch due to reasons other than VF, was 6.7 (3.5-7.1)
and 2.7 (2.3-3.7) years in the NN and PIr groups,
respectively (p=0.0078). The median difference (95% CI)
in first regimen monthly ART costs and in monthly
non-ART costs was, respectively, 348€ (287€-410€)a n d
23€(11€-35€), with lower costs for the NN group. Initi-
ating therapy with 2NRTI+NN reduces the average
number of switches by 17%, saves 18,943€ per individual
and increases life expectancy by 1.3 months due to the
impact of the accumulated number of regimens on
future events.
Conclusions
This study suggests that, when clinically valid, initiating
therapy with 2NRTI+NN is a cost-saving strategy and
equally effective when compared to 2NRTI+PI as the
first regimen.
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